Cannabis Research on DYSTONIA dating from 1981-2016
Science & Research
2016 - Study ~ Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacological Research.
American Society for Experimental Neurotherapeutics.
Harefuah - Israel Medical Association.
2006 - Study ~ Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. Cambridge University, CNS Spectrums.
2005 - Study ~ Cannabis sativa and dystonia secondary to Wilson's disease. Journal of the International Parkinson and Movement Disorder Society.
2004 - Study ~ Cannabinoid agonists in the treatment of blepharospasm--a case report study. Neuro Endocrinol Letters.2002 - Study ~ A Dramatic Response to Inhaled Cannabis in a Woman with Central Thalamic Pain and Dystonia. Journal of Pain and Symptom Management.
1999 - Study ~ Cannabis in movement disorders. Forsch Komplementarmed
1994 - Study ~ (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. European Journal of Pharmacology.
1986 - Study ~ Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience.
1986 - Study ~ Cannabidiol (CBD) in dystonic movement disorders. Clinical Studies and Case Reports.
1985 - Study ~ Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia. Clinical Studies and Case Reports.
Journal, Volume,Issue - Abstract IACM 2nd Conference on Cannabinoids in Medicine, September 12-13, 2003, Cologne
Major outcome(s) - Positive effects of THC in children with severe neurological disorders
Indication - Spasticity; Dystonia; Epilepsy; Anxiety.
Medication - Delta-9-THC
Routes(s) - Oral
Dose(s) - 0.04 - 0.14 mg/kg body weight
Duration (days) - Unavailable
Participant(s) - 8 children with different neurological disorders
Design - Uncontrolled case report
Type of publication - Meeting abstract
Address of author(s) - Paediatrician, Brunnenstrasse 54, 34537 Bad Wildungen, Germany
8 patients – children or adolescents aged 3 to 14 years – have been treated with delta 9 THC, dosages ranged from 0.04 mg/kg body weight to 0.14 mg/kg body weight.
In an 8 year-old-boy with NCL Jansky-Bielschowsky spasticity was diminished, he became more alert and his mood improved.
In a 12 year-old-girl, who had suffered from severe hypoxia during birth, mood improved, awareness was increased and focal seizures (presenting as nystagmus and versive movement) but not tonic-clonic seizures were reduced.
A 12 year-old-girl with PDHC-deficiency became more interested in her surroundings and society. Nodding spasms and tonic seizures decreased.
In a 14 year-old-girl with marked dystonia due to NCL Spielmeyer-Vogt a reduction of abnormal movement patterns was observed. In addition the girl had more initiative.
In a 13 year-old-boy presenting with spasticity, athetosis, myoclonic movements and epileptic seizures of unknown cause interest in his surroundings was improved, myoclonic movements were less intense but of similar frequency. Frequency and duration of his focal and generalized seizures were not influenced.
In an 11 year-old-girl with a traumatic paraplegia a significant improvement of symptoms of a post traumatic reaction presenting as an eating disorder and negative behaviour was observed. Taking higher doses the girl started to develop side effects including inappropriate language (concerning sexual content) and very associative thinking. Therapy was discontinued without signs of withdrawal.
In a 3 10/12 year-old-boy with a traumatic paraplegia a significant improvement in his behaviour and eating disorder was observed.
In a 14 year-old-boy suffering from intractable epilepsy and severe mental retardation appetite and mood improved. Frequency of seizures seemed not to be influenced, but clear assessment was not possible because antiepileptic drugs were changed.
Conclusion: In severly disabled children and adolescents delta 9 THC medication can have positive psychotropic effects, influences the degree of spasticity and dystonia and-occasionally-seems to have an anticonvulsant action.